Which has preferable earnings & valuation, ICLR or IQV?

IQVIA has higher revenue and earnings than Icon. IQVIA is trading at a lower price-to-earnings ratio than Icon, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Icon $8.25B 1.60 $229.34M $4.26 40.43 IQVIA $16.31B 2.63 $1.36B $8.06 32.28

Is ICLR or IQV more profitable?

IQVIA has a net margin of 8.10% compared to Icon's net margin of 3.99%. IQVIA's return on equity of 30.25% beat Icon's return on equity. Company Net Margins Return on Equity Return on Assets Icon 3.99% 8.02% 4.56% IQVIA 8.10% 30.25% 6.54%

Does the media refer more to ICLR or IQV?

In the previous week, IQVIA had 23 more articles in the media than Icon. MarketBeat recorded 28 mentions for IQVIA and 5 mentions for Icon. Icon's average media sentiment score of 1.57 beat IQVIA's score of 1.49 indicating that Icon is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Icon 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive IQVIA 24 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation and earnings, MEDP or IQV?

IQVIA has higher revenue and earnings than Medpace. IQVIA is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Medpace $2.53B 6.85 $451.12M $17.06 36.39 IQVIA $16.31B 2.63 $1.36B $8.06 32.28

Is MEDP or IQV more profitable?

Medpace has a net margin of 17.67% compared to IQVIA's net margin of 8.10%. Medpace's return on equity of 110.15% beat IQVIA's return on equity. Company Net Margins Return on Equity Return on Assets Medpace 17.67% 110.15% 24.84% IQVIA 8.10% 30.25% 6.54%

Does the media favor MEDP or IQV?

In the previous week, IQVIA had 3 more articles in the media than Medpace. MarketBeat recorded 28 mentions for IQVIA and 25 mentions for Medpace. IQVIA's average media sentiment score of 1.49 beat Medpace's score of 1.10 indicating that IQVIA is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Medpace 20 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive IQVIA 24 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings and valuation, TECH or IQV?

IQVIA has higher revenue and earnings than Bio-Techne. IQVIA is trading at a lower price-to-earnings ratio than Bio-Techne, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Bio-Techne $1.22B 9.32 $181.86M $1.15 62.89 IQVIA $16.31B 2.63 $1.36B $8.06 32.28

Is TECH or IQV more profitable?

Bio-Techne has a net margin of 14.97% compared to IQVIA's net margin of 8.10%. IQVIA's return on equity of 30.25% beat Bio-Techne's return on equity. Company Net Margins Return on Equity Return on Assets Bio-Techne 14.97% 13.23% 10.61% IQVIA 8.10% 30.25% 6.54%

Does the media favor TECH or IQV?

In the previous week, IQVIA had 13 more articles in the media than Bio-Techne. MarketBeat recorded 28 mentions for IQVIA and 15 mentions for Bio-Techne. IQVIA's average media sentiment score of 1.49 beat Bio-Techne's score of 1.20 indicating that IQVIA is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bio-Techne 11 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive IQVIA 24 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer IQV or A?

In the previous week, Agilent Technologies had 4 more articles in the media than IQVIA. MarketBeat recorded 32 mentions for Agilent Technologies and 28 mentions for IQVIA. IQVIA's average media sentiment score of 1.49 beat Agilent Technologies' score of 1.36 indicating that IQVIA is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment IQVIA 24 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Agilent Technologies 26 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor IQV or CRL?

In the previous week, IQVIA had 18 more articles in the media than Charles River Laboratories International. MarketBeat recorded 28 mentions for IQVIA and 10 mentions for Charles River Laboratories International. IQVIA's average media sentiment score of 1.49 beat Charles River Laboratories International's score of 0.53 indicating that IQVIA is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment IQVIA 24 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Charles River Laboratories International 5 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

IQVIA (IQV) Competitors

$260.17 +4.12 (+1.61%)

As of 08/21/2026 03:58 PM Eastern

Compare

IQV vs. ICLR, MEDP, TECH, A, and CRL

Should you buy IQVIA stock or one of its competitors? IQVIA's main competitors and comparable companies include Icon (ICLR), Medpace (MEDP), Bio-Techne (TECH), Agilent Technologies (A), and Charles River Laboratories International (CRL). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "life sciences tools & services" industry.

How does IQVIA compare to Icon?

Icon (NASDAQ:ICLR) and IQVIA (NYSE:IQV) are both large-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, media sentiment, analyst recommendations, dividends, profitability, valuation, risk and earnings.

95.6% of Icon shares are held by institutional investors. Comparatively, 89.6% of IQVIA shares are held by institutional investors. 44.0% of Icon shares are held by company insiders. Comparatively, 1.7% of IQVIA shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, IQVIA had 23 more articles in the media than Icon. MarketBeat recorded 28 mentions for IQVIA and 5 mentions for Icon. Icon's average media sentiment score of 1.57 beat IQVIA's score of 1.49 indicating that Icon is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Icon	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
IQVIA	24 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

IQVIA has higher revenue and earnings than Icon. IQVIA is trading at a lower price-to-earnings ratio than Icon, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Icon	$8.25B	1.60	$229.34M	$4.26	40.43
IQVIA	$16.31B	2.63	$1.36B	$8.06	32.28

IQVIA has a net margin of 8.10% compared to Icon's net margin of 3.99%. IQVIA's return on equity of 30.25% beat Icon's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Icon	3.99%	8.02%	4.56%
IQVIA	8.10%	30.25%	6.54%

Icon currently has a consensus price target of $170.40, suggesting a potential downside of 1.06%. IQVIA has a consensus price target of $241.88, suggesting a potential downside of 7.03%. Given Icon's higher possible upside, equities research analysts clearly believe Icon is more favorable than IQVIA.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Icon	2 Sell rating(s)	7 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.41
IQVIA	0 Sell rating(s)	3 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.88

Icon has a beta of 1.21, meaning that its share price is 21% more volatile than the broader market. Comparatively, IQVIA has a beta of 1.18, meaning that its share price is 18% more volatile than the broader market.

Summary

IQVIA beats Icon on 10 of the 16 factors compared between the two stocks.

How does IQVIA compare to Medpace?

Medpace (NASDAQ:MEDP) and IQVIA (NYSE:IQV) are both large-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, earnings, media sentiment, dividends, valuation and profitability.

78.0% of Medpace shares are held by institutional investors. Comparatively, 89.6% of IQVIA shares are held by institutional investors. 20.5% of Medpace shares are held by insiders. Comparatively, 1.7% of IQVIA shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Medpace has a net margin of 17.67% compared to IQVIA's net margin of 8.10%. Medpace's return on equity of 110.15% beat IQVIA's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Medpace	17.67%	110.15%	24.84%
IQVIA	8.10%	30.25%	6.54%

IQVIA has higher revenue and earnings than Medpace. IQVIA is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Medpace	$2.53B	6.85	$451.12M	$17.06	36.39
IQVIA	$16.31B	2.63	$1.36B	$8.06	32.28

Medpace has a beta of 1.15, indicating that its stock price is 15% more volatile than the broader market. Comparatively, IQVIA has a beta of 1.18, indicating that its stock price is 18% more volatile than the broader market.

In the previous week, IQVIA had 3 more articles in the media than Medpace. MarketBeat recorded 28 mentions for IQVIA and 25 mentions for Medpace. IQVIA's average media sentiment score of 1.49 beat Medpace's score of 1.10 indicating that IQVIA is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Medpace	20 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
IQVIA	24 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Medpace presently has a consensus target price of $584.18, suggesting a potential downside of 5.89%. IQVIA has a consensus target price of $241.88, suggesting a potential downside of 7.03%. Given Medpace's higher possible upside, equities research analysts plainly believe Medpace is more favorable than IQVIA.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Medpace	0 Sell rating(s)	10 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.23
IQVIA	0 Sell rating(s)	3 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.88

Summary

IQVIA beats Medpace on 9 of the 17 factors compared between the two stocks.

How does IQVIA compare to Bio-Techne?

Bio-Techne (NASDAQ:TECH) and IQVIA (NYSE:IQV) are both large-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, analyst recommendations, profitability, institutional ownership, dividends, media sentiment and valuation.

99.0% of Bio-Techne shares are owned by institutional investors. Comparatively, 89.6% of IQVIA shares are owned by institutional investors. 1.3% of Bio-Techne shares are owned by company insiders. Comparatively, 1.7% of IQVIA shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Bio-Techne has a net margin of 14.97% compared to IQVIA's net margin of 8.10%. IQVIA's return on equity of 30.25% beat Bio-Techne's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bio-Techne	14.97%	13.23%	10.61%
IQVIA	8.10%	30.25%	6.54%

Bio-Techne has a beta of 1.28, suggesting that its share price is 28% more volatile than the broader market. Comparatively, IQVIA has a beta of 1.18, suggesting that its share price is 18% more volatile than the broader market.

Bio-Techne presently has a consensus price target of $68.92, suggesting a potential downside of 4.70%. IQVIA has a consensus price target of $241.88, suggesting a potential downside of 7.03%. Given Bio-Techne's higher probable upside, equities research analysts plainly believe Bio-Techne is more favorable than IQVIA.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bio-Techne	1 Sell rating(s)	14 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.06
IQVIA	0 Sell rating(s)	3 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.88

IQVIA has higher revenue and earnings than Bio-Techne. IQVIA is trading at a lower price-to-earnings ratio than Bio-Techne, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bio-Techne	$1.22B	9.32	$181.86M	$1.15	62.89
IQVIA	$16.31B	2.63	$1.36B	$8.06	32.28

In the previous week, IQVIA had 13 more articles in the media than Bio-Techne. MarketBeat recorded 28 mentions for IQVIA and 15 mentions for Bio-Techne. IQVIA's average media sentiment score of 1.49 beat Bio-Techne's score of 1.20 indicating that IQVIA is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bio-Techne	11 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
IQVIA	24 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

IQVIA beats Bio-Techne on 10 of the 17 factors compared between the two stocks.

How does IQVIA compare to Agilent Technologies?

IQVIA (NYSE:IQV) and Agilent Technologies (NYSE:A) are both large-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, dividends, risk, institutional ownership, media sentiment, valuation, profitability and analyst recommendations.

IQVIA has higher revenue and earnings than Agilent Technologies. Agilent Technologies is trading at a lower price-to-earnings ratio than IQVIA, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IQVIA	$16.31B	2.63	$1.36B	$8.06	32.28
Agilent Technologies	$6.95B	6.47	$1.30B	$4.98	31.98

In the previous week, Agilent Technologies had 4 more articles in the media than IQVIA. MarketBeat recorded 32 mentions for Agilent Technologies and 28 mentions for IQVIA. IQVIA's average media sentiment score of 1.49 beat Agilent Technologies' score of 1.36 indicating that IQVIA is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
IQVIA	24 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Agilent Technologies	26 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

IQVIA has a beta of 1.18, indicating that its share price is 18% more volatile than the broader market. Comparatively, Agilent Technologies has a beta of 1.25, indicating that its share price is 25% more volatile than the broader market.

IQVIA presently has a consensus target price of $241.88, suggesting a potential downside of 7.03%. Agilent Technologies has a consensus target price of $160.24, suggesting a potential upside of 0.62%. Given Agilent Technologies' stronger consensus rating and higher probable upside, analysts clearly believe Agilent Technologies is more favorable than IQVIA.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IQVIA	0 Sell rating(s)	3 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.88
Agilent Technologies	0 Sell rating(s)	4 Hold rating(s)	13 Buy rating(s)	2 Strong Buy rating(s)	2.89

89.6% of IQVIA shares are held by institutional investors. 1.7% of IQVIA shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Agilent Technologies has a net margin of 19.55% compared to IQVIA's net margin of 8.10%. IQVIA's return on equity of 30.25% beat Agilent Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IQVIA	8.10%	30.25%	6.54%
Agilent Technologies	19.55%	24.33%	12.99%

Summary

IQVIA and Agilent Technologies tied by winning 8 of the 16 factors compared between the two stocks.

How does IQVIA compare to Charles River Laboratories International?

IQVIA (NYSE:IQV) and Charles River Laboratories International (NYSE:CRL) are both large-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, media sentiment, institutional ownership, profitability, earnings and risk.

IQVIA has a beta of 1.18, meaning that its share price is 18% more volatile than the broader market. Comparatively, Charles River Laboratories International has a beta of 1.38, meaning that its share price is 38% more volatile than the broader market.

In the previous week, IQVIA had 18 more articles in the media than Charles River Laboratories International. MarketBeat recorded 28 mentions for IQVIA and 10 mentions for Charles River Laboratories International. IQVIA's average media sentiment score of 1.49 beat Charles River Laboratories International's score of 0.53 indicating that IQVIA is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
IQVIA	24 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Charles River Laboratories International	5 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

IQVIA presently has a consensus price target of $241.88, suggesting a potential downside of 7.03%. Charles River Laboratories International has a consensus price target of $255.65, suggesting a potential downside of 13.41%. Given IQVIA's stronger consensus rating and higher possible upside, equities research analysts clearly believe IQVIA is more favorable than Charles River Laboratories International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IQVIA	0 Sell rating(s)	3 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.88
Charles River Laboratories International	1 Sell rating(s)	3 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.69

IQVIA has higher revenue and earnings than Charles River Laboratories International. Charles River Laboratories International is trading at a lower price-to-earnings ratio than IQVIA, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IQVIA	$16.31B	2.63	$1.36B	$8.06	32.28
Charles River Laboratories International	$4.02B	3.51	-$144.34M	-$4.85	N/A

89.6% of IQVIA shares are owned by institutional investors. Comparatively, 98.9% of Charles River Laboratories International shares are owned by institutional investors. 1.7% of IQVIA shares are owned by company insiders. Comparatively, 1.3% of Charles River Laboratories International shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

IQVIA has a net margin of 8.10% compared to Charles River Laboratories International's net margin of -5.96%. IQVIA's return on equity of 30.25% beat Charles River Laboratories International's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IQVIA	8.10%	30.25%	6.54%
Charles River Laboratories International	-5.96%	15.75%	6.51%

Summary

IQVIA beats Charles River Laboratories International on 14 of the 17 factors compared between the two stocks.

Get IQVIA News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IQV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IQV vs. The Competition

Export

Metric	IQVIA	Life Sciences Tools & Services Industry	Healthcare Sector	NYSE Exchange
Market Cap	$42.77B	$10.24B	$7.38B	$24.31B
Dividend Yield	N/A	1.45%	2.53%	3.70%
P/E Ratio	32.28	61.54	272.60	30.31
Price / Sales	2.63	110.99	623.33	21.00
Price / Cash	14.54	27.04	78.62	32.49
Price / Book	6.80	37.34	13.05	6.77
Net Income	$1.36B	$56.67B	$3.47B	$1.07B
7 Day Performance	10.16%	5.24%	2.09%	-0.65%
1 Month Performance	25.65%	9.02%	6.64%	3.38%
1 Year Performance	36.22%	24.45%	25.02%	14.90%

IQVIA Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IQV IQVIA	3.947 of 5 stars	$260.17 +1.6%	$241.88 -7.0%	+36.2%	$42.77B	$16.31B	32.28	93,000	News Coverage Positive News
ICLR Icon	3.703 of 5 stars	$169.45 +3.9%	$170.40 +0.6%	-2.0%	$12.49B	$8.25B	39.78	40,100	Positive News
MEDP Medpace	3.5558 of 5 stars	$597.12 +3.2%	$584.18 -2.2%	+33.9%	$16.15B	$2.53B	35.00	6,200	Trending News Insider Trade
TECH Bio-Techne	3.2183 of 5 stars	$72.39 0.0%	$68.92 -4.8%	+26.7%	$11.34B	$1.22B	62.95	3,100	News Coverage Positive News Analyst Forecast
A Agilent Technologies	4.5125 of 5 stars	$148.65 +0.1%	$160.24 +7.8%	+31.1%	$41.95B	$6.95B	29.85	18,100	News Coverage Positive News Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:IQV) was last updated on 8/23/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

IQVIA (IQV) Competitors